Last reviewed · How we verify

Oral Levonadifloxacin/Linezolid Tablet

Wockhardt · Phase 3 active Small molecule

Oral Levonadifloxacin/Linezolid Tablet is a Fluoroquinolone/Oxazolidinone combination antibiotic Small molecule drug developed by Wockhardt. It is currently in Phase 3 development for Bacterial infections (specific indications in Phase 3 development not publicly detailed).

This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria.

This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria. Used for Bacterial infections (specific indications in Phase 3 development not publicly detailed).

At a glance

Generic nameOral Levonadifloxacin/Linezolid Tablet
SponsorWockhardt
Drug classFluoroquinolone/Oxazolidinone combination antibiotic
TargetDNA gyrase, topoisomerase IV, 50S ribosomal subunit
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Levonadifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Linezolid is an oxazolidinone that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides synergistic activity against a broad spectrum of gram-positive and gram-negative bacteria, including resistant strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral Levonadifloxacin/Linezolid Tablet

What is Oral Levonadifloxacin/Linezolid Tablet?

Oral Levonadifloxacin/Linezolid Tablet is a Fluoroquinolone/Oxazolidinone combination antibiotic drug developed by Wockhardt, indicated for Bacterial infections (specific indications in Phase 3 development not publicly detailed).

How does Oral Levonadifloxacin/Linezolid Tablet work?

This combination drug inhibits bacterial DNA gyrase (via levonadifloxacin) and bacterial protein synthesis (via linezolid) to kill or stop the growth of susceptible bacteria.

What is Oral Levonadifloxacin/Linezolid Tablet used for?

Oral Levonadifloxacin/Linezolid Tablet is indicated for Bacterial infections (specific indications in Phase 3 development not publicly detailed).

Who makes Oral Levonadifloxacin/Linezolid Tablet?

Oral Levonadifloxacin/Linezolid Tablet is developed by Wockhardt (see full Wockhardt pipeline at /company/wockhardt).

What drug class is Oral Levonadifloxacin/Linezolid Tablet in?

Oral Levonadifloxacin/Linezolid Tablet belongs to the Fluoroquinolone/Oxazolidinone combination antibiotic class. See all Fluoroquinolone/Oxazolidinone combination antibiotic drugs at /class/fluoroquinolone-oxazolidinone-combination-antibiotic.

What development phase is Oral Levonadifloxacin/Linezolid Tablet in?

Oral Levonadifloxacin/Linezolid Tablet is in Phase 3.

What are the side effects of Oral Levonadifloxacin/Linezolid Tablet?

Common side effects of Oral Levonadifloxacin/Linezolid Tablet include Nausea, Diarrhea, Headache, Vomiting, Thrombocytopenia.

What does Oral Levonadifloxacin/Linezolid Tablet target?

Oral Levonadifloxacin/Linezolid Tablet targets DNA gyrase, topoisomerase IV, 50S ribosomal subunit and is a Fluoroquinolone/Oxazolidinone combination antibiotic.

Related